Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peng Bao-gang is active.

Publication


Featured researches published by Peng Bao-gang.


The Chinese-german Journal of Clinical Oncology | 2003

Fixed-Tumor Vaccine: A Practical Formulation with Cytokine-Microspheres for Protective and Therapeutic Antitumor Immunity

Peng Bao-gang; Liang Lijian; Liu Shuqin; Huang Jie-fu; He Qiang; Lu Mingde; Leong Kam W; Ohno Tadao

Objective: To study the protective and therapeutic antitumor immunity against hepatocellular carcinoma (HCC) with the fixed-tumor vaccine.Methods: A tumor vaccine consisting of fixed tumor cells or fixed tumor fragments combined with sustained-releasers of cytokines and a non-toxic adjuvant was developed. C57BL/6J mice were immunized intra-dermally with the vaccine on day 0 and 7, followed by intrahepatic challenge with live Hepa 1–6 cells.Results: All of 15 nonimmunized control mice developed the hepatoma. Protection of mice immunized with fixed Hepa 1–6 cells and both of IL-2/GM-CSF microspheres or further mixed with TiterMax Gold reached 80% and 87%, respectively. Mass growth of the established tumors, vaccinated twice at 5 mm in diameter, the tumor of control animals continued to grow. However, 7–10 days after the second injection of the tumor vaccine, the tumor growth was suppressed in 9 of 10 mice and then markedly reduced. Complete tumor regression was observed in 60% (6/10) of mice. Splenocytes from the control mice were not able to lyse target Hepa 1–6 cells and other tumor cells. In contrast splenocytes from the vaccinated mice exhibited a 41% lytic activity against the Hepa 1–6 cells tested at an effector/target (E/T) ratio of 5, whereas they did not exhibited such activity against the melanoma cells (B16-F1), Lewis lung carcinoma cells (LLC), renal carcinoma cells (Renca), and bladder carcinoma cells (MBT-2). The cytotoxic activity was inhibited by the treatment with anti-CD3, anti-CD8, and anti-MHC-class I monoclonal antibodies but not with anti-CD4 and anti-MHC-class II antibodies. In the Phase-I clinical trial, vaccination of HCC patients with the autologous vaccine is a well-tolerated treatment and induces fixed tumor fragment-specific immunity.Conclusion: Fixed HCC vaccination elicited protective and therapeutic antitumor immunity against HCC. The tumor vaccine elicited antigen specific CTL response lysis of the target HCC was mediated by the typical MHC-class I restricted CD8+ T cells.


Chinese Journal of Cancer Research | 1994

Two-stages resection for advanced hepatocellular carcinoma

Liang Lijian; Lu mingde; Huang Jiefu; Peng Bao-gang

We performed two-stage resection for sixteen patients with advanced hepatocellular carcinoma from January, 1987 to July, 1991. All patients underwent various surgical therapies prior to resection which included gauze packing hemostasis in 1 case, hyperthermia plus radiotherapy in 1, hepatic arterial ligation in 2, operative hepatic arterial embolization in 3, and transcatheter embolization in 9. The median interval between the first therapy and tumour resection was 59 days with a range of 29--769 days, and the median diameter of tumours decreased from 10.5 cm to 7.5 cm. The majority of precedures on two-stage resection were irregular hepatectomy or Iobectomy under occlusion of porta hepatis. Regular hepatectomies were done in 4 cases. Pathalogical examination showed complete coagulation necrosis in 3 specimens. However, in the others were still found residual viable tumours. Survival periods of the patients who received two-stage resection were from 4 months to 4 years except 2 operative death. The significance, possibility as well as methods of two-stage resection were discussed.We performed two-stage resection for sixteen patients with advanced hepatocellular carcinoma from January, 1987 to July, 1991. All patients underwent various surgical therapies prior to resection which included gauze packing hemostasis in 1 case, hyperthermia plus radiotherapy in 1, hepatic arterial ligation in 2, operative hepatic arterial embolization in 3, and transcatheter embolization in 9. The median interval between the first therapy and tumour resection was 59 days with a range of 29--769 days, and the median diameter of tumours decreased from 10.5 cm to 7.5 cm. The majority of precedures on two-stage resection were irregular hepatectomy or Iobectomy under occlusion of porta hepatis. Regular hepatectomies were done in 4 cases. Pathalogical examination showed complete coagulation necrosis in 3 specimens. However, in the others were still found residual viable tumours. Survival periods of the patients who received two-stage resection were from 4 months to 4 years except 2 operative death. The significance, possibility as well as methods of two-stage resection were discussed.


Chinese Journal of Pathophysiology | 2011

Relationship between expression level of TIMP-3 and invasion/metastasis of hepatocellular carcinoma

Peng Bao-gang


Chinese Journal of General Surgery | 2012

Thermal ablation for subcutaneously implanted hepatocellular carcinoma in mice

Peng Bao-gang


Chinese Journal of Pathophysiology | 2011

Tumor stages and peripheral blood lymphocyte subsets in patients with AFP-L3-positive hepatocellular carcinoma

Peng Bao-gang


Chinese Journal of Digestive Surgery | 2009

Prognostic effect of modified loop choledochojejunostomy.

Li Shaoqiang; Liang Lijian; Peng Bao-gang; Huang Li; Chen Dong


Zhongguo Bingli Shengli Zazhi | 2008

IN SITUマイクロ波アブレーションは抗肝癌免疫反応の誘導に有効な抗原を提供する。【JST・京大機械翻訳】

Kuang Ming; Lu Mingde; Zhou Qi; Peng Bao-gang; Liang Lijian; Huang Jiefu


Zhongguo Bingli Shengli Zazhi | 2007

ERBB2によって誘導される腫瘍の形成と浸潤はFAK機能に依存する。【JST・京大機械翻訳】

He Qiang; Huang Meijin; Peng Bao-gang; Liang Lijian; Shen Shunli; Zhou Fan


Chinese Journal of Pathophysiology | 2007

Suppression of tumor growth by mRNA DC vaccine in severe combined immune deficiency mouse

Peng Bao-gang


Chinese Journal of Pathophysiology | 2007

Expressions of VEGF,ANG-1,ANG-2 and TSP-1 in cholangiocellular carcinoma and relationship with tumor angiogenesis,differentiation,invasion and metastasis

Peng Bao-gang

Collaboration


Dive into the Peng Bao-gang's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

He Qiang

Sun Yat-sen University

View shared research outputs
Top Co-Authors

Avatar

Huang Jiefu

Sun Yat-sen University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Lu Mingde

Sun Yat-sen University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Leong Kam W

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Liu Shuqin

Johns Hopkins University

View shared research outputs
Researchain Logo
Decentralizing Knowledge